Aug. 29, 2012 College News - Julie Biller, MD, Professor of Medicine and Pediatrics and Director of the Adult Cystic Fibrosis Program, was asked to testify on behalf of the national Cystic Fibrosis Foundation at the Sept. 15 open public hearing of the U.S. Food and Drug Administration’s Anti-Infective Drugs Advisory Committee. Dr. Biller will speak in support of tobramycin inhalation powder (TIP) for treatment of cystic fibrosis.
Dr. Biller has treated cystic fibrosis patients for more than 20 years and has participated in a phase three clinical trial of TIP, which can be used to help cystic fibrosis patients manage bacterium Pseudomonas aeruginosa infections.